How often has an athlete come to your practice assuming that spending one week every month with fatigue, bloating and cravings is normal?
Our challenge with premenstrual syndrome is neither to accept it helplessly nor to treat all its symptoms as the same thing, but to understand the biochemistry of the late luteal phase so that we can offer effective nutritional support in everyday life.
In this article, we analyse the pathophysiology of the cycle and review evidence-based tools for addressing it in practice.

1. What is premenstrual syndrome (PMS)?
Premenstrual syndrome (PMS) is a group of symptoms that recur during the late luteal phase, approximately 4 to 10 days before a period, and disappear when bleeding begins.
During the initial clinical history, it is important to distinguish clearly between three situations that frequently overlap but require different approaches:
- Premenstrual syndrome (PMS): A condition of neuroendocrine origin. It results from hormonal fluctuations in the days before a period and affects mood, eating behaviour (increased appetite or specific cravings), perceived performance and fluid balance (fluid retention).
- Dysmenorrhoea (acute menstrual pain): Cramping pain caused by uterine contractions and a temporary reduction in blood supply to the area (uterine ischaemia) during bleeding. Although it can coincide with PMS in the preceding days, menstrual pain is a mechanical and inflammatory problem, rather than PMS itself.
- Premenstrual dysphoric disorder (PMDD): The severe clinical form of PMS. It involves serious emotional and mood disturbances, such as profound depression, extreme irritability or functional impairment, which go beyond nutritional management and require multidisciplinary care with referral to psychology and mental health professionals.
PMS affects 75% of women and is disabling in 20% to 40% of cases. PMDD is less prevalent than PMS, affecting 5% [6].
If your patient experiences irritability, disproportionate fatigue and intense cravings for sweet or fatty foods for around 5 days before her period, you are facing a neuroendocrine challenge (PMS), rather than simply period pain (dysmenorrhoea).
Identifying this distinction at the first interview helps prevent errors when adjusting energy availability or recommending micronutrients.
2. Hormonal physiology of the menstrual cycle and premenstrual syndrome (PMS)
To understand what happens towards the end of the cycle, we first need to locate the late luteal phase, approximately days 21 to 28 in a standard cycle. This follows a follicular phase of development and ovulation, after which the follicle becomes the corpus luteum. If implantation does not occur, the corpus luteum stops functioning, causing a sharp, simultaneous fall in oestrogen and progesterone.
We all experience this hormonal decline. The clinical question is: if falling hormone levels are a normal physiological process, why do some athletes develop PMS while others do not?

Because PMS does not originate in the hormonal decline itself, but in how the body responds to that fluctuation. In clinical practice, we see this impact triggered through two entirely different pathways:
The role of progesterone: genuine deficiency or allosteric hypersensitivity?
When assessing progesterone in practice, we encounter two clearly distinct pathophysiological pathways that require opposite clinical approaches:
- Pathway 1: genuine luteal phase insufficiency (progesterone deficiency)
The corpus luteum is functionally weak and produces an insufficient amount of progesterone, with mid-luteal blood test values below 10 ng/mL. This is a common scenario in athletes exposed to low energy availability, high training loads or chronically elevated cortisol that suppresses the gonadotropic axis.
This creates relative hyperoestrogenism. Without enough progesterone to act as a brake, oestrogen predominates, increasing capillary permeability, peripheral fluid retention, inflammation and breast tenderness.
Here, our priority is indeed to restore luteal function and endogenous progesterone production. This means ensuring adequate calorie availability, managing metabolic stress and considering herbal therapies, as discussed later.
- Pathway 2: cellular and neurochemical hypersensitivity (normal progesterone)
The patient’s blood tests are within range, with physiological progesterone levels > 10 ng/mL in the mid-luteal phase. The problem is qualitative rather than quantitative: her central nervous system has a hyperreactive response or altered allosteric sensitivity to the natural decline in the hormone and its metabolites, such as allopregnanolone.
In this case, the hormonal decline destabilises GABA-A receptor sensitivity and alters central serotonergic tone. Even with ideal blood hormone levels, the athlete experiences anxiety, irritability, emotional lability, insomnia and cravings.
Trying to raise progesterone in this profile will not provide any benefit. Our intervention should focus on cushioning the neurochemical impact in the brain by supporting GABA and serotonin pathways, and limiting the pro-inflammatory cascade.
Latent prolactin as a stress-related aggravating factor
Disturbances in the progesterone pathway are often accompanied by a third factor: latent or functional prolactin.
Metabolic stress from high-intensity training, disrupted circadian rhythms or everyday psychological and emotional demands reduces hypothalamic dopaminergic inhibition. This triggers a functional or latent rise in prolactin during the late luteal phase.
This functional hyperprolactinaemia increases vascular permeability and the inflammatory response in breast tissue, directly exacerbating cyclical mastalgia (severe breast pain) and reducing overall ovulatory cycle quality. Identifying this factor in the clinical history can point us towards dopaminergic modulators such as Vitex agnus-castus or cofactors such as vitamin B6.
3. The most common symptoms of premenstrual syndrome
The scientific literature describes more than 150 symptoms associated with the late luteal phase. Facing such a broad range in everyday work with athletes can be overwhelming, so it is helpful to group the most common manifestations into three areas:
- Physical symptoms:
Breast tenderness (mastalgia), peripheral fluid retention, nausea, vomiting, vascular headaches, acne, tiredness, altered bowel habits (alternating constipation and diarrhoea) and pelvic heaviness.
- Emotional symptoms
Irritability, anxiety, depressed mood, mood swings and reduced tolerance of frustration.
- Behavioural symptoms
Hunger, sleep disturbances (difficulty falling asleep or early waking), increased appetite or compulsive food cravings, poor concentration and changes in libido.
Beyond physical discomfort, female athletes also commonly experience a period of mismatch between their actual effort and perceived performance. During the late luteal phase, they often report disproportionate fatigue (high RPE) at paces or training loads they managed comfortably two weeks earlier. Recognising this in the clinical history helps prevent the athlete from interpreting reduced performance as a loss of fitness or a failure of discipline or commitment.
4. Pain (dysmenorrhoea): why do cramps occur and what role does nitric oxide play?
Although dysmenorrhoea is a mechanical and inflammatory manifestation distinct from PMS, we regularly see athletes in whom both conditions coexist.
- The pain mechanism: The hormonal decline before bleeding triggers a large release of pro-inflammatory prostaglandins, mainly PGF2α. These substances cause intense myometrial contractions that compress the uterine vasculature, drastically reducing oxygen supply (uterine ischaemia). This tissue hypoxia is directly responsible for acute, cramping pain.
- The role of nitric oxide (NO): In response to this vasoconstriction, enhancing the nitric oxide (NO) pathway through diet or supplementation allows us to induce direct vasodilation in uterine smooth muscle, restore microcirculation and reduce the increased muscle tone that causes pain. We will explore this in more detail later.
5. The relationship between premenstrual syndrome, appetite and eating behaviour
Increased appetite and food cravings towards the end of the cycle do not appear by magic or because of a lack of willpower. They reflect a real neuroendocrine adjustment. Specifically, we see:
- A sharp fall in serotonin and oestrogen: Falling oestrogen reduces central serotonin, decreasing satiety and prompting a search for carbohydrates and fats to restore that pathway.
- Changes in satiety signals: Progesterone fluctuations alter the secretion of gut hormones such as GLP-1 and CCK, disrupting normal fullness signalling.
- Higher basal metabolic expenditure: Progesterone’s thermogenic action can increase resting energy expenditure by 100 to 300 kcal/day. In other words, the athlete feels hungrier because she is using more energy.
Maintaining a strict calorie deficit is very likely to raise cortisol and anxiety, often leading to compulsive eating or even guilt. In this context, planning an increase in calorie intake over these days, with more flexibility or an adaptive maintenance week, could be beneficial.
Attempting to maintain a strict calorie deficit during this window is very likely to raise cortisol and anxiety, often leading to compulsive eating and even guilt. In this context, the most sensible approach is to plan an increase in calorie intake over these days, allowing greater flexibility or an adaptive maintenance week.
This is where technology becomes a valuable clinical ally: INDYA’s software lets us make temporary macronutrient adjustments or offer more recipe flexibility without a large time investment.
6. The role of nutrition in managing premenstrual syndrome
We need to be honest: nutrition does not cure PMS or magically reverse it, but it is a fundamental foundation for reducing its impact.
Scientific evidence on isolated dietary interventions for PMS remains limited and heterogeneous. As a multifactorial condition with a strong genetic and neurochemical component, nutrition modulates the body’s response but does not act as a sole or definitive treatment.
What nutrition CAN do
- Ensure energy availability: Maintaining adequate calorie intake (LEA > 30 kcal/kg FFM/day) is the first line of defence against suppression of the gonadotropic axis and genuine luteal phase insufficiency (pathway 1).
- Modulate low-grade inflammation: A nutrient-dense diet including fruit, vegetables, pulses, nuts and spices is associated with less intense premenstrual symptoms. By contrast, Western dietary patterns rich in ultra-processed foods and trans fats exacerbate the pro-inflammatory cascade.
- Support hormonal regulation: Meeting micronutrient requirements supports protein synthesis, liver function in oestrogen clearance and metabolic stability.
What we CANNOT promise in practice
Nutrition does not resolve the underlying neurochemical causes or receptor allosteric hypersensitivity (pathway 2). It acts on the consequences, modulating severity and preventing a pro-inflammatory or low-energy environment from worsening episodes.
Explaining this clearly helps the athlete understand that we are offering a biomechanical and metabolic strategy, rather than promising miracles, so that her body has the nutritional foundation it needs. For professionals, ensuring that everyday meal plans maintain this nutrient density is precisely where INDYA’s automated recipes and meal patterns save planning time.
7. Micronutrients and targeted supplementation for PMS
In everyday practice, the aim is not to prescribe a generic PMS supplement combination, but to select targeted supplementation according to the patient’s dominant pathophysiological pathway, distinguishing interventions with strong support from secondary tools.
Modulating pathway 1 and physical inflammation (dysmenorrhoea).
Vitex agnus-castus (dry extract)
Its active compounds act as dopamine agonists, suppressing prolactin and restoring progesterone in pathway 1. It is therefore a neuroendocrine modulator, rather than an occasional painkiller.
In latent hyperprolactinaemia or luteal insufficiency, treatment should continue for 3 to 4 menstrual cycles because its effect is cumulative. After 3–4 months of continuous use, it is stopped to reassess the athlete’s response.
Reference dose: 4 mg/day of standardised ethanolic extract, equivalent to 30–40 mg of dried plant, or 100–500 mg/day of standardised dry extract. For powdered fruit with a lower phytochemical concentration, doses rise to 600–1,200 mg/day.
It would be useful only in natural cycles with genuine luteal insufficiency. It has no rationale in athletes using hormonal contraceptives, whose axis is suppressed exogenously, and is contraindicated alongside dopaminergic drugs or antipsychotics.
Ginger and omega-3:
Ginger, through gingerols and shogaols, acts as a dual inhibitor of the COX-2 and 5-LOX pathways, blocking the pro-inflammatory PGF2α prostaglandin cascade, as ibuprofen does. Omega-3 fatty acids replace arachidonic acid in myometrial cell membranes, reducing the synthesis of pro-inflammatory eicosanoids.
The reference ginger dose is 750–2,000 mg/day as dry extract or powder, divided into 3–4 doses from 2–3 days before the period until the third day of bleeding.
The omega-3 dose would be 1,000–2,000 mg/day of combined EPA/DHA.
Nitric oxide precursors (inorganic nitrates):
The nitrate–nitrite–nitric oxide pathway induces direct vasodilation in uterine smooth muscle. Reversing the myometrial vasoconstriction and ischaemia caused by prostaglandins reduces the tissue hypoxia responsible for acute, cramping pain.
The reference dose would be 300–500 mg of inorganic nitrates, approximately 5–8 mmol, daily from concentrated beetroot juice or standardised extracts, taken during the 3–5 days before menstruation.
Vitamin B6 (pyridoxine/pyridoxal-5-phosphate):
It is an essential enzymatic cofactor in the conversion of L-DOPA to dopamine through aromatic L-amino acid decarboxylase. By enhancing hypothalamic dopaminergic tone, it activates the natural brake on lactotroph cells, reducing functional hyperprolactinaemia and mastalgia (pathway 1).
It also acts directly as a cofactor in the central synthesis of GABA through glutamate decarboxylase and serotonin through 5-HTP, helping to reduce irritability and cravings (pathway 2).
The reference dose would be 25–50 mg/day of pyridoxine for limited periods of 4–12 weeks to avoid peripheral sensory neuropathy caused by accumulation.
Modulating pathway 2 and neurochemistry
Magnesium
Magnesium is a key element in managing pathway 2. It acts as a positive allosteric modulator at GABA-A receptors, counteracting the neurochemical hyperexcitability caused by allopregnanolone fluctuations. It also reduces muscle tension and supports overnight recovery.
The reference dose would be 200–400 mg/day of elemental magnesium, preferably as bisglycinate because of its greater bioavailability and digestive tolerability.
Secondary herbal therapies (saffron and enhanced turmeric)
Although the heterogeneity of studies means they should be considered second-line tools, the evidence is promising.
- For saffron extract (Crocus sativus), its active compounds, crocin and safranal, inhibit serotonin and dopamine reuptake in the synaptic space. It could be useful in pathway 2 for athletes with marked irritability, mood instability or compulsive cravings. The reference dose would be 30 mg/day of standardised dry extract containing 2% safranal.
- High-bioavailability turmeric (enhanced curcumin): It inhibits the nuclear transcription factor NF-kB and reduces pro-inflammatory cytokines, acting as a secondary pain-modulating and systemic support tool. The reference dose would be 200–500 mg/day of bioavailable curcumin, divided into two doses during the 7 days before bleeding.
8. A practical approach in nutrition consultations
Nutrition education
One of our most powerful roles is providing nutrition education that empowers the athlete. Our patient should fully understand the nutritional decisions we make and the reasons behind each one.
Explaining what PMS is, how it affects metabolism and why meeting energy, macronutrient and micronutrient needs is essential, with particular attention to iron during menstruation, helps remove guilt and greatly improves adherence.
Biofeedback and symptom tracking
Before making nutritional changes or recommending supplementation, we need data. It is very useful for the athlete to record symptoms over 2 to 3 consecutive menstrual cycles in three key areas: somatic and physical symptoms (nausea, mastalgia, etc.), emotional symptoms (irritability, premenstrual sadness, anxiety, etc.) and behavioural symptoms (sleep changes, reduced concentration, cravings, etc.).
This monitoring allows us to distinguish pathway 1 (luteal insufficiency/hyperprolactinaemia) from pathway 2 (allosteric hypersensitivity).
Turning complexity into practical meal plans
Adjusting energy intake, coordinating supplements, managing cravings… Trying to organise all of this manually for every patient takes an enormous amount of time. INDYA’s software greatly simplifies the logistics so that we can focus on what matters:
- Cycle synchronisation: The app connects to health applications such as Apple Health or Garmin, allowing us to see the athlete’s cycle phase without constantly having to ask her.

- Straightforward energy adjustments: Increasing intake by 100–300 kcal in the luteal phase takes just a few clicks, adapting the plan to the week’s actual expenditure.
- Flexibility for cravings: The extensive recipe database and recipe-swapping feature provide valuable support for greater flexibility. They offer many alternatives that help match nutritional needs with the recipes the athlete actually feels like eating at that moment.
- Direct communication and follow-up: Through weekly assessments, adherence tracking and the in-app chat, athletes can tell us how they feel so that we can adapt to their needs as they arise.
9. FAQs – Premenstrual syndrome
¿La nutrición puede reducir los síntomas del SPM?
Una pauta bien estructurada es clave para amortiguar los síntomas: reduce la inflamación, estabiliza la glucemia y evita que la baja disponibilidad energética altere la función del cuerpo lúteo.
¿Qué micronutrientes son clave en el SPM?
Destacamos el magnesio, las vitaminas del grupo B, el calcio, los nitratos inorgánicos, el zinc y la vitamina D.
¿Es normal aumentar el apetito antes de la menstruación?
Sí, es puramente fisiológico. La progesterona eleva el gasto metabólico basal en la fase lútea. Sumado a la caída de serotonina, el cuerpo pide más energía.
¿Cuándo es necesario derivar a otro profesional?
Saber dónde termina el ámbito nutricional es imprescindible para garantizar la seguridad de la deportista. Cuando el cuadro clínico sobrepasa nuestro alcance, la prioridad es la derivación a compañeros de otras especialidades:
– A ginecología: Ante dismenorrea incapacitante o sospecha de patología orgánica subyacente (endometriosis, SOP, miomas o quistes).
– A psicología / psiquiatría: Si identificamos alteración emocional grave o sospecha de TDPM. La nutrición es un pilar de base, pero ante patología estructural o riesgo de salud mental, el trabajo interdisciplinar es innegociable.
10. References
- Tiranini L, Nappi RE. Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Fac Rev. 2022;11:11.
- Premenstrual syndrome. In: MSD Manual Professional Version [Internet]. Kenilworth (NJ): Merck & Co., Inc.; [cited 2026 Mar 31]. Available from: https://www.msdmanuals.com/
- Siminiuc R, Ţurcanu D. Impact of nutritional diet therapy on premenstrual syndrome. Front Nutr. 2023;10:1079417.
- González L. Nutrición y hormonas: cómo la alimentación afecta a nuestro ciclo menstrual. Revisión bibliográfica. Rev Electrónica PortalesMedicos.com. 2025;20(23):1123.
- Malik R, Anwar I, Ikram M. Association between meal skipping and premenstrual syndrome among young females. Pakistan Journal of Health Sciences. 2025;6(4):271–277. doi:10.54393/pjhs.v6i4.2555
- Candan E, Erokay Metin Z, Tengilimoglu-Metin MM. The role of premenstrual syndrome in hedonic hunger and food craving during the menstrual cycle. J Nutr Sci. 2025;14:e66. doi:10.1017/jns.2025.10038. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11075635/
- Rogan M, Black K. Dietary energy intake across the menstrual cycle: a narrative review. Nutr Rev [Internet]. 2022 [cited 28 October 2023];81(7):869–886. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251302/


